Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00505830
Recruitment Status : Unknown
Verified July 2007 by Groupe Francais d'Epidemiologie Psychiatrique.
Recruitment status was:  Recruiting
First Posted : July 25, 2007
Last Update Posted : July 25, 2007
Sponsor:
Collaborator:
Joint Clinical Research Center
Information provided by:
Groupe Francais d'Epidemiologie Psychiatrique

Tracking Information
First Submitted Date July 23, 2007
First Posted Date July 25, 2007
Last Update Posted Date July 25, 2007
Study Start Date July 2007
Primary Completion Date Not Provided
Current Primary Outcome Measures Not Provided
Original Primary Outcome Measures Not Provided
Change History No Changes Posted
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome: AQ, EQ and SQ
Official Title Evaluation of the French Version of Screening Questionnaires for Autism and Asperger Syndrome : Autism Spectrum Quotient (AQ) Empathy Quotient (EQ) and Systemizing Quotient (SQ)
Brief Summary

Autism is considered as an invading disorder of the development. Asperger Syndrome (AS) is a particular form of autism and is difficult to diagnose. The Autism Spectrum Quotient (AQ) has been developed in order to measure the degree of autistic traits in autistic adolescent with normal intelligence (Baron-Cohen et al. 2001, 2006). AQ comprises 50 questions, with 5 groups of 10 questions assessing imagination, social skills, attention switching, attention to detail and communication skills. Each of these items scores 1 point if the respondent records abnormal or autistic like behaviour. The minimum score on the AQ is 0 and the maximum 50.

The principal objective of this study is to evaluate the accuracy of the French version of Autism Spectrum Quotient questionnaire.

Secondary objectives are to:

Evaluate if EQ and SQ can distinguish adolescents without psychiatric syndromes from those with classical autism or AS.

Evaluate if AQ, EQ and SQ can distinguish adolescents with psychiatric disorders from autistic adolescents.

Define the threshold of positivity for the 3 questionnaires.

Detailed Description

4 groups of participants will be screened with the questionnaires: Group 1: 50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.

Group 2: 50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.

Group 3: 50 adolescents with psychiatric disorders. Group 4: Sample of 50 healthy adolescents selected randomly from 200. The questionnaires are given to the parents of adolescents during the first meeting. Parents are invited to send them back to the clinical investigation centre of Lyon (France).

Multicentre study: 8 clinical centres and 18 paediatricians

Study Type Observational
Study Design Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Not Provided
Study Population Not Provided
Condition
  • Asperger Syndrome
  • Autism
Intervention Other: questionnaires

Primary outcome:

Autism Spectrum Quotient (AQ)

Secondary outcome measure:

Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score

Study Groups/Cohorts
  • Case: 1
    50 adolescents with AS or high functioning autism (HFS) diagnosed by psychiatrists using established criteria and with an IQ >85.
    Intervention: Other: questionnaires
  • Case: 2
    50 adolescents with AS or classical autism diagnosed by psychiatrists using established criteria 70<IQ<84.
    Intervention: Other: questionnaires
  • Control: 3
    50 adolescents with psychiatric disorders but no autism syndrom.
    Intervention: Other: questionnaires
  • Control: 4
    Sample of 50 healthy adolescents selected randomly from 200.
    Intervention: Other: questionnaires
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: July¬†23,¬†2007)
450
Original Estimated Enrollment Same as current
Estimated Study Completion Date July 2009
Primary Completion Date Not Provided
Eligibility Criteria

Inclusion Criteria:

Group 1 (AS/HFA) and 2 (AS/classic autism) :

  • Boys and girls aged 12 to 18
  • Patients with autism or Asperger syndrome according to the diagnostic criteria (ICD 10)
  • Patients receiving education in an ordinary school
  • IQ>70

Group 3 (adolescents with psychiatric disorders):

  • Boys and girls aged 12 to 18
  • Patients hospitalized on a psychiatric ward or at a psychiatrics patient visit or psychiatric consultation wit hout autistic syndrome
  • Patients receiving education in an ordinary school when not in hospital

Group 4 (adolescent without psychiatric syndrome):

  • Boys and girls aged 12 to 18
  • Patients receiving education in an ordinary school

Exclusion Criteria:

For all groups :

  • Problem with language or comprehension
  • Participants who have not given their consent
Sex/Gender
Sexes Eligible for Study: All
Ages 12 Years to 18 Years   (Child, Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries France
Removed Location Countries  
 
Administrative Information
NCT Number NCT00505830
Other Study ID Numbers Autisme AQ
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor Groupe Francais d'Epidemiologie Psychiatrique
Collaborators Joint Clinical Research Center
Investigators
Principal Investigator: Sabine Manificat, MDH Centre Hospitalier Saint Jean de Dieu
PRS Account Groupe Francais d'Epidemiologie Psychiatrique
Verification Date July 2007